Quarterly report pursuant to Section 13 or 15(d)

REVENUES FROM CONTRACTS WITH CUSTOMERS

v3.23.1
REVENUES FROM CONTRACTS WITH CUSTOMERS
 3 Months Ended
Mar. 31, 2023
REVENUES FROM CONTRACTS WITH CUSTOMERS  
REVENUES FROM CONTRACTS WITH CUSTOMERS

NOTE 16. REVENUES FROM CONTRACTS WITH CUSTOMERS

Disaggregation of Net Revenues

The Company’s net product revenues are summarized as follows:

​

​

​

​

​

​

​

​

​

​

Three-Month Period Ended March 31, 

($ in thousands)

    

2023

    

2022

Qbrexza®

​

$

4,094

​

$

7,376

Accutane®

​

 

4,648

​

 

4,907

Amzeeq®

​

​

1,193

​

​

3,466

Targadox®

​

​

793

​

​

2,634

Ximino®

​

​

612

​

​

967

Exelderm®

​

 

511

​

 

704

Zilxi®

​

​

314

​

​

741

Other branded revenue

​

 

—

​

 

1

Total product revenues

​

$

12,165

​

$

20,796

​

The above table includes the authorized generic product within the line items for Targadox®, Ximino® and Exelderm®.

Significant Customers

For the three-month periods ended March 31, 2023 and 2022, there were no customers that accounted for more than 10% of the Company’s total gross product revenue.

At March 31, 2023, one of the Company’s customers accounted for more than 10% of its total accounts receivable balance at 13.7%. At December 31, 2022, two of the Company’s customers accounted for more than 10% of its total accounts receivable balance at 16.7% and 10.4%.

Other Revenue

​

​

​

​

​

​

​

​

​

    

Three-Month Period Ended March 31,

($ in thousands)

    

2023

    

2022

Other revenue

 

$

48

 

$

2,500

Total other revenue

​

$

48

​

$

2,500

​

Other revenue for the three-month period ended March 31, 2023 reflects year-to-date royalties of $48,000 on sales of Rapifort® Wipes 2.5%. in Japan, from Maruho Co., LTD. (“Maruho”), our exclusive out-licensing partner in Japan. Other revenue for the three-month period ended March 31, 2022 reflects a net $2.5 million milestone payment from Maruho. In January 2022, Maruho received manufacturing and marketing approval in Japan for Rapifort® Wipes 2.5% (Japanese equivalent to U.S. FDA approved QBREXZA®), for the treatment of primary axillary hyperhidrosis, triggering the net payment.